Motivest Use In Pregnancy & Lactation





United Lab
Full Prescribing Info
Use In Pregnancy & Lactation
Use in Pregnancy: Pregnancy Category C: There are no adequate and well-controlled clinical studies on the use of fluoxetine in pregnant women. Fluoxetine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Nonteratogenic Effects: Neonates exposed to fluoxetine, SNRIs, or SSRIs late in the third trimester have developed complications which required prolonged hospitalization, respiratory support and tube feeding. The following clinical manifestations have been reported: respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. These features are consistent with either a direct toxic effect of SNRIs and SSRIs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome.
Exposure of infants to SSRIs during late pregnancy may increase the risk for persistent pulmonary hypertension of the newborn (PPHN). However, this clinical finding has not been firmly established.
Labor and Delivery: Fluoxetine's effect on labor and delivery is unknown. Its use during labor and delivery should be limited to cases where clinical benefits clearly outweigh the potential risk to the fetus.
Use in Lactation: Prescribing fluoxetine to breastfeeding mothers is strongly discouraged because a considerable amount of fluoxetine and its metabolites are excreted in breastmilk.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in